Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL +0.05%55 Days Sales Outstanding is 137.42 as of Jun. 2026, which is 109% above its 10-year median of 65.66. GuruFocus rates SLGL with a GF Score™ of 55/100 and a GF Value™ of $67.24 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 835 Biotechnology companies, Sol-Gel Technologies ranks worse than 73.05% on this metric.
Sol-Gel Technologies (NAS:SLGL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sol-Gel Technologies Days Sales Outstanding Related Terms
Sol-Gel Technologies Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs SABS, BCYC, CYDY: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Days Sales Outstanding falls into.
Sol-Gel Technologies Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 137.42 mean?
Sol-Gel Technologies (SLGL) has a Days Sales Outstanding of 137.42 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sol-Gel Technologies and its competitors. This is 109% above median its historical median of 65.66. Over the past decade, Sol-Gel Technologies' Days Sales Outstanding has ranged from 51.56 to 616.97. According to the industry distribution chart, Sol-Gel Technologies ranks #610 out of 835 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Sol-Gel Technologies' Days Sales Outstanding too high?
Sol-Gel Technologies' current Days Sales Outstanding of 137.42 is 109% above median its 10-year median of 65.66. Over the past 10 years, this metric has ranged from a low of 51.56 to a high of 616.97. The Biotechnology industry median Days Sales Outstanding is 68.95. Sol-Gel Technologies' value of 137.42 is 99.3% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #610 out of 835 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Days Sales Outstanding compare to SABS and BCYC?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #610 out of 835 companies for Days Sales Outstanding. This places Sol-Gel Technologies in the lower half of its industry. The industry median Days Sales Outstanding is 68.95. Sol-Gel Technologies' value of 137.42 is 99.3% above this benchmark. Historically, Sol-Gel Technologies' own Days Sales Outstanding has ranged from 51.56 to 616.97 over the past decade. While the company's 10-year median is 65.66 vs. the industry median of 68.95, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.95, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Days Sales Outstanding of 137.42 is 99.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Days Sales Outstanding is 137.42, which is 109% above median its own 10-year median of 65.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $67.24, compared to a current price of $77.73 — trading 15.6% above its estimated fair value. The current Days Sales Outstanding is 137.42, which is 109% above median its 10-year median of 65.66 and 99.3% above the Biotechnology industry median of 68.95. Sol-Gel Technologies' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Days Sales Outstanding is 137.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $77.73 is trading 15.6% above its estimated GF Value™ of $67.24.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Days Sales Outstanding: 137.42 (109% above median its 10-year median of 65.66)
GF Value™: $67.24 vs. price of $77.73 (15.6% above fair value)
Industry Position: 99.3% above the Biotechnology median (#610 of 835)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for SLGL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
